Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database.
Martin M, Nguyen HM, Beuvon C, Bene J, Palassin P, Atzenhoffer M, Rouby F, Sassier M, Pérault-Pochat MC, Roblot P, Allouchery M, Puyade M; French Network of Regional Pharmacovigilance Centers. Martin M, et al. Among authors: sassier m. Cancers (Basel). 2022 Oct 14;14(20):5030. doi: 10.3390/cancers14205030. Cancers (Basel). 2022. PMID: 36291814 Free PMC article.
Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population.
Hillaire-Buys D, Mousset M, Allouchery M, Azzouz B, Babin M, Bellet F, Béné J, Default A, Durrieu G, Géniaux H, Grandvuillemin A, Gras-Champel V, Jantzem H, Lambert A, Lepelley M, Massy N, Petitpain N, Rocher F, Sanchez-Pena P, Sassier M, Simon C, Triquet L, Valnet-Rabier MB, Veyrac G, Faillie JL, Zenut MC. Hillaire-Buys D, et al. Among authors: sassier m. Therapie. 2020 Sep-Oct;75(5):471-480. doi: 10.1016/j.therap.2019.08.001. Epub 2019 Oct 28. Therapie. 2020. PMID: 31732241
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M; French Network of Regional Pharmacovigilance Centers. Allouchery M, et al. Among authors: sassier m. J Immunother Cancer. 2020 Dec;8(2):e001622. doi: 10.1136/jitc-2020-001622. J Immunother Cancer. 2020. PMID: 33428586 Free PMC article.
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
Gauci ML, Boudou P, Baroudjian B, Vidal-Trecan T, Da Meda L, Madelaine-Chambrin I, Basset-Seguin N, Bagot M, Pages C, Mourah S, Resche-Rigon M, Pinel S, Sassier M, Rouby F, Eftekhari P, Lebbé C, Gautier JF. Gauci ML, et al. Among authors: sassier m. Cancer Immunol Immunother. 2018 Aug;67(8):1197-1208. doi: 10.1007/s00262-018-2178-0. Epub 2018 May 28. Cancer Immunol Immunother. 2018. PMID: 29808365 Free PMC article.
47 results